Rua Bioscience (RUA)•FY23•Released 29 August 2023$2.5m cash versus $5.9m operating burn leaves a thin runwayRevenue leapt 14-fold off a tiny base and the PBT loss narrowed 20%, but H2 swung to a $6.7m NPAT loss and FCF stayed at -$6.0m.Published 23 April 2026Read briefing→
Rua Bioscience (RUA)•HY23•Released 28 February 2023Rua books NZ$0.7m profit on NZ$62.8k revenue while cash burn holds near NZ$3.7mHeadline swing from loss to profit sits alongside an unchanged operating cash outflow and a 24.5% drawdown in the cash balance, pointing to a...Published 23 April 2026Read briefing→
Rua Bioscience (RUA)•FY22•Released 29 August 2022Revenue collapsed 94.6% and NPAT loss widened to $8.6m on tax reversalOperating cash burn accelerated to $6.8m while cash reserves fell to $1.9m, shortening the runway despite borrowings being cleared.Published 22 April 2026Read briefing→
Rua Bioscience (RUA)•HY22•Released 25 February 2022Cash dropped to NZ$2.3m as operating burn nearly doubled to NZ$3.7mRevenue grew 34% off a trivial base while the cash position fell 88% year on year, leaving runway as the central question heading into...Published 22 April 2026Read briefing→